Included in the formulation
Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):VED
ONLS
АТХ:A.03.A.A.04 Mebeverin
A.03.A.A Synthetic holinoblokatory - ethers with tertiary amino group
Pharmacodynamics:Spasmolytic of myotropic action. Has a direct effect on the smooth muscles of the gastrointestinal tract. Eliminates spasm without affecting normal intestinal motility.
Does not possess anticholinergic action.
It blocks fast sodium channels of the myocyte cell membrane and disrupts the entry of Na + ions into the cell, blocks the entrance of Ca2 + ions through slow channels, slows down the membrane depolarization process and prevents the contraction of muscle fibers.
Pharmacokinetics:After oral administration is not found in the plasma,since it undergoes presystemic hydrolysis in the liver with the formation of 3,4-dimethoxybenzoic acid (veratric acid) and mebeverin alcohol. It is excreted mainly with urine exclusively in the form of metabolites - veratric acid and mebeverin alcohol (including partially in the form of the corresponding carboxylic acid, partially as a demethylated carboxylic acid), in small amounts it is determined in bile. Mebeverin in unmodified form is not excreted from the body, it is completely metabolized; its metabolites are almost completely eliminated from the body. Veratric acid is excreted by the kidneys. Mebeverine alcohol is also excreted by the kidneys, partly in the form of a carboxylic acid and partly as a demethylated carboxylic acid.
Do not cumulate.
Indications:In adults: spasm of the digestive tract (including caused by organic disease), intestinal colic, biliary colic; irritable bowel syndrome (symptomatic treatment of pain and spasms, as well as intestinal disorders and discomfort).
In children older than 12 years: functional disorders of the gastrointestinal tract, accompanied by pain in the abdomen.
XI.K20-K31.K30 Dyspepsia
XI.K55-K63.K58 Irritable Bowel Syndrome
XI.K55-K63.K59.9 Functional bowel disorder, unspecified
XVIII.R10-R19.R10.1 Pain localized in the upper abdomen
XVIII.R10-R19.R10.4 Other and unspecified abdominal pain
Contraindications:Hypersensitivityintestinal obstruction, children under 12 years old.
Carefully:Breastfeeding, porphyria, bladder fibrosis.
Pregnancy and lactation:When pregnancy is possible, if the expected effect of therapy exceeds the potential risk to the fetus. When used in therapeutic doses mebeverin does not penetrate into breast milk.
The category of FDA recommendations is not defined. Adequate and well-controlled studies in humans have not been conducted. In experiments on animals teratogenic action was not revealed.
Dosing and Administration:Take inside 100 mg 4 times or 135 mg 3 times a day. When the desired clinical effect is achieved, the dose is gradually reduced within a few weeks.
Side effects:Dizziness (in some cases), diarrhea or constipation; allergic reactions (urticaria, Quincke's edema, face edema and exanthema).
Overdose:Symptoms: excitation of the central nervous system.
Treatment: removal of non-absorbed drug from the digestive tract (lavagestomach, the appointment of activated charcoal), symptomatic and supportive therapy. The specific antidote is unknown.
Interaction:Not described.
Special instructions:During the treatment period it is necessary to refrain from driving motor vehicles and practicing potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions.